What's Happening?
Ionis Pharmaceuticals and AstraZeneca have reported that their phase 3 trial of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoint. The trial, known as CARDIO-TTRansform, aimed to assess the drug's
impact on cardiovascular mortality and recurrent clinical events. Despite the setback, a subgroup analysis showed a nominally significant result for eplontersen monotherapy. The trial involved 1,432 participants across 20 countries and is the largest of its kind for ATTR-CM. The companies plan to present the full data at the European Society of Cardiology Congress.
Why It's Important?
The trial's outcome is a setback for Ionis and AstraZeneca, as it affects the potential market expansion for eplontersen in treating ATTR-CM. The results highlight the complexities of treating this progressive and often fatal condition, which affects a significant number of patients worldwide. The findings may influence future research and treatment strategies for ATTR-CM, as well as the competitive landscape in the market. Despite the trial's failure, Ionis remains optimistic about its pipeline and future prospects.
What's Next?
Ionis and AstraZeneca will continue to analyze the trial data to gain insights into the treatment landscape for ATTR-CM. The companies plan to share the results with the scientific community at the upcoming European Society of Cardiology Congress. This analysis may guide future clinical trials and inform treatment decisions for ATTR-CM. Ionis also plans to focus on its broader portfolio and pipeline, aiming to deliver new medicines and achieve financial goals in the coming years.
